Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company’s proprietary antibody drug discovery platform.
Apexigen has raised $165.38MM with the following series: $48.43MM for Series A-1 and A-2, $115.22MM for Series B, $343.82MM for Series C, $48.43MM for Series A-1 and A-2, $115.22MM for Series B, $343.82MM for Series C.